Exploring implications of the CRLs signature in clinical treatment
IPS
To determine whether the prognostic signature can help predict patient response to immunotherapy, the immunophenoscore (IPS) of CTLA-4 and PD-1 inhibitors in CC patients was obtained from the TCIA database. When differences in IPS between risk subgroups are compared, a higher score indicates a better response rate to ICI immunotherapy. The next step is to observe whether the prognostic signature can be used to predict which drugs will be effective prior to a patient being treated. We applied the “pRophetic” R package to calculate the half maximal inhibitory concentration (IC50) values of chemotherapeutic drugs commonly used in the clinic. The Wilcoxon signed-rank test was used to compare the IC50 values of the high- and low-risk cohorts. A statistically significant 